ED 30. Effects of the testosterone replacement therapy and tadalafil on Chinese patients of diabetic erectile dysfunction with hypogonadism

Objective: Aim of this study for evaluate the efficacy of the combined therapy of tadalafil and testosterone replacement therapy in management of diabetic erectile dysfunction (DMED) combined with hypogonadism.

Subjects and Methods: Forty-three patients of DMED with hypogonadism were reviewed and the combined therapy of tadalafil and testosterone replacement therapy were evaluated. According to the penentration insertion condition, the patients were divided into 2 groups: insertion-able (A group), un-insertion (B group). All of patients oral administration testosterone undecanoate (120 mg/d) and on demanded Tadalafil (10 mg) twice a week for group A and Tadalafil (20 mg) twice a week for group B, and the treatment period was 3 months. as a control group (C), thirty patients with DMED (average 45.61 years old) were treated only Tadalafil (10 mg) twice a week.The serum testosterone level, IIEF-5 score and Padam score were used for evaluation the clinical efficacious.All the patients had the desire to improve the sexual life. This group was aged 32-57 years old (average 46.35 years old), course of disease was above 2 years, blood sugar was well controlled, testosterone level was under 3 ng/mL. Treatment approach as below: and regularity sex life in therapeutic session. Reuse the IIEF-5 score and Padam score and recheck the testosterone level after treatment. testosterone level was 2.87±0.54 ng/mL (normal control: 5.23±2.42 ng/mL, consult scope: 2-10 ng/mL) before therapy.

Results: The average score of the IIEF-5 was 18.25±7.38 after therapy, it was significantly higher (P<0.01) than that of 12.36±5.73 before therapy. The average score of the Padam score was 31.73±4.36 before therapy, compared with 18.41±2.75 after therapy, the score was obviously descent, the difference had statistics significance (P<0.01). Compared with control group C, the score of the IIEF-5 and the Padam score were significantly affected (P<0.01) in group A and B after therapy, The average level of testosterone was 3.26±0.62 ng/mL after therapy, it was no statistics significance (P>0.05) compared with that before therapy. The sex life of 38 pts were improved obviously. 26 pts of A group had got better sex life, among 17 pts of B group pts, 12 pts could insert, the sex life obviously improved, but for the rest 5 pts still remained un-insert, they would need further therapy.

Conclusions: The combination treatment with twice a week dosage of tadalafil and testosterone replacement therapy is a new effective way for the treatment of DMED.